Clinical Trial: A Phase 2b Study of Zagociguat in Patients With MELAS

U.S., May 7 -- ClinicalTrials.gov registry received information related to the study (NCT06402123) titled 'A Phase 2b Study of Zagociguat in Patients With MELAS' on May 2.

Brief Summary: PRIZM is a Phase 2b randomized, double-blind, placebo-controlled, 3-treatment, 2-period, crossover study evaluating the efficacy and safety of oral zagociguat 15 and 30 mg vs. placebo when administered daily for 12 weeks in participants with genetically and phenotypically defined MELAS.

Study Type: Interventional

Condition: Mitochondrial Encephalopathy, Lactic Acidosis and Stroke-Like Episodes (MELAS Syndrome)

Intervention: * Drug: zagociguat 15mg

Once-daily oral tablets

* Drug: zagociguat 30mg

Once-daily oral tablets

* Drug: Placebo

Once-daily ora...